Author: Gupta, Aakriti; Madhavan, Mahesh V.; Poterucha, Timothy J.; DeFilippis, Ersilia M.; Hennessey, Jessica A.; Redfors, Bjorn; Eckhardt, Christina; Bikdeli, Behnood; Platt, Jonathan; Nalbandian, Ani; Elias, Pierre; Cummings, Matthew J.; Nouri, Shayan N.; Lawlor, Matthew; Ranard, Lauren S.; Li, Jianhua; Boyle, Claudia; Givens, Raymond; Brodie, Daniel; Krumholz, Harlan M.; Stone, Gregg W.; Sethi, Sanjum S.; Burkhoff, Daniel; Uriel, Nir; Schwartz, Allan; Leon, Martin B.; Kirtane, Ajay J.; Wan, Elaine Y.; Parikh, Sahil A.
Title: Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19 Cord-id: z4ulrekw Document date: 2021_2_26
ID: z4ulrekw
Snippet: The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1(st) through Ma
Document: The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1(st) through May 12(th), 2020 with study period ending on June 11(th), 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, p < 0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and administration timing: 1
- acute ards respiratory distress syndrome and admission prior: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- acute ards respiratory distress syndrome and liver disease chronic kidney disease: 1, 2, 3
- acute lung injury and adjunctive therapy: 1, 2, 3
- acute lung injury and administration timing: 1, 2, 3, 4
- acute lung injury and admission prior: 1
- acute lung injury and admission time: 1, 2, 3
- acute lung injury and liver disease: 1, 2, 3, 4, 5, 6, 7
- adjunctive therapy and administration timing: 1
- adjunctive therapy and admission time: 1, 2
- adjunctive therapy and liver disease: 1, 2
- admission prior and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- admission prior and liver disease chronic kidney disease: 1
- admission time and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- admission time and liver disease chronic kidney disease: 1
Co phrase search for related documents, hyperlinks ordered by date